Inloggad som:

Cartitude-6

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

Cartitude-6
En randomiserad fas 3-studie som jämför Daratumumab, Bortezomib, Lenalidomide och Dexametason (DVRd) följt av Ciltacabtagene Autoleucel kontra Daratumumab, Bortezomib, lenalidomid och dexametason (DVRd) följt av autolog stamcell Transplantation (ASCT) hos deltagare med nyligen diagnostiserat multipelt myelom som är Transplantation kvalificerad
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
PLACEHOLDER
Mer information om studien för vårdgivare
* 18 years of age or older.* Measurable disease, as assessed by central laboratory, at screening as defined by any of the following:a Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or b. Light-chain MM without measurable disease in serum or urine
*Prior treatment with CAR-T therapy directed at any target. *Any prior BCMA target therapy * Any prior therapy for MM or smoldering myeloma other than a short course ofcorticosteroids.
Behandling
Fas 3
Ej tillämpbar
Akademisk

Studien ändrades senast av: Akademiska sjukhus (2024-05-13)

Tillbaka till listan